// App-Quantinova.ai

4698 : BET protein inhibitors prevent TKI-induced drug resistance in solid tumors

Researchers

Presenter

  • Yuan Zhao

Principal Investigators

  • Yiyuan Wu

  • Hexiang Wang

  • Bo Ren

  • Ye Liu

  • Min Wei

  • Changyou Zhou

  • Lusong Luo

Medical Centers

  • BeiGene (Beijing) Co., Ltd., Beijing, China

Locations

  • China

Companies

  • BeiGene (Beijing) Co

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Hematological malignancies

  • Solid malignancies

  • Lymphomas

Biomarkers

  • cMYC

Drug/Treatment

  • Vemurafenib

  • Erlotinib hydrochloride

  • L-Tyrosine

  • Molibresib

Outcome

  • N/A

Study Design

  • Adaptive

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved